Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2003

View Archived Issues

Benzimidazole CDK4 inhibitors under study at Aventis

Merck scientists present a novel GABA-A agonist for use in anxiety and convulsions

Fuji Photo Film claims new contrast agents for the diagnosis of vascular disorders

New HIV protease inhibitors in early development at BMS

Pfizer patent covers novel thyroid receptor ligands and their use

Dithiazole-based MMP inhibitors newly discovered at Shiseido

Vitamin E analogue sensitizes Jurkat cells by suppressing NF-kB activation

Restructuring update at CeNeS

Arava approved for rheumatoid arthritis in Japan

Ketek may exacerbate symptoms of myasthenia gravis

Vilazodone results fail to support progression to phase III

Northwest Biotherapeutics receives NCI grant for tumor growth inhibition

Nastech reacquires intranasal apomorphine rights following Pfizer-Pharmacia merger

DynPort completes smallpox vaccine phase I trial

Patient treatment begins in phase I trial of VIT-100

Phase II studies of ILX-651 planned

Virulizin phase III trial extended to Canada and Mexico

Ribozyme changes name

AGI Dermatics regains rights to Dimericine

Novo Nordisk and Fournier sign repaglinide comarketing deal for Europe

Vasopeptidase inhibitor as effective as ACE inhibitor in old SHR

Tricyclic bis-enone compounds as inhibitors of NO production

Profile of SLV-310, a potential antipsychotic agent

5-HT6 receptor-selective antagonist reverses cognitive deficits in animal model

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026